Samsung Biologics hereby provides the following overview of the guiding direction of our shareholder return policy, with a clear emphasis on the creation of sustainable, long-term value for our shareholders.
As part of our commitment to strengthening competitiveness in the global biopharmaceutical CDMO industry and securing a sustainable growth foundation, Samsung Biologics will continue to advance a broad range of large-scale investments, including domestic investments in Bio Campus II and III, overseas expansion, as well as strategic M&A in technologies and manufacturing capabilities.
Against this strategic backdrop, Samsung Biologics believes that the most responsible deployment of capital at this stage is to support both financial soundness and execution excellence, while channeling resources preferentially toward our core growth priorities. Through this disciplined approach, we seek to enhance corporate value over the long term, and in turn, deliver enduring value to our shareholders.
This investment-led capital strategy is intended not merely to address our immediate growth objectives, but to establish a robust foundation upon which a more sustainable and resilient shareholder return policy can be built in the years ahead.
We will reassess our shareholder return policy after three years, taking into careful consideration of our business environment, progress of our investment initiatives, our cash generation profile, and overall financial position, and will provide further guidance as appropriate.
Samsung Biologics will continue to engage in transparent and constructive communication with our shareholders, as we pursue a capital allocation policy that remains closely aligned with their interests and our long-term growth trajectory.
Samsung Biologics hereby provides the following overview of the guiding direction of our shareholder return policy, with a clear emphasis on the creation of sustainable, long-term value for our shareholders.
As part of our commitment to strengthening competitiveness in the global biopharmaceutical CDMO industry and securing a sustainable growth foundation, Samsung Biologics will continue to advance a broad range of large-scale investments, including domestic investments in Bio Campus II and III, overseas expansion, as well as strategic M&A in technologies and manufacturing capabilities.
Against this strategic backdrop, Samsung Biologics believes that the most responsible deployment of capital at this stage is to support both financial soundness and execution excellence, while channeling resources preferentially toward our core growth priorities. Through this disciplined approach, we seek to enhance corporate value over the long term, and in turn, deliver enduring value to our shareholders.
This investment-led capital strategy is intended not merely to address our immediate growth objectives, but to establish a robust foundation upon which a more sustainable and resilient shareholder return policy can be built in the years ahead.
We will reassess our shareholder return policy after three years, taking into careful consideration of our business environment, progress of our investment initiatives, our cash generation profile, and overall financial position, and will provide further guidance as appropriate.
Samsung Biologics will continue to engage in transparent and constructive communication with our shareholders, as we pursue a capital allocation policy that remains closely aligned with their interests and our long-term growth trajectory.
- CDO
- CGMP
- ADC
- Bio Campus
- IR
- CMO